Your browser doesn't support javascript.
loading
A 10-year retrospective study of antibacterial-induced thrombocytopenia in a women and children hospital using China Hospital Pharmacovigilance System and Visual Basic for Applications.
Yang, Jianhui; Cai, Can; Pan, Xiuming; Chen, Weida; Zhuang, Wei; Lin, Wanlong; Chen, Yao.
Afiliación
  • Yang J; Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
  • Cai C; Research and Innovation Center, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
  • Pan X; Research and Innovation Center, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
  • Chen W; Research and Innovation Center, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
  • Zhuang W; Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
  • Lin W; Department of Pharmacy, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
  • Chen Y; Research and Innovation Center, Women and Children's Hospital, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Br J Clin Pharmacol ; 2024 Apr 10.
Article en En | MEDLINE | ID: mdl-38600727
ABSTRACT

AIMS:

We aimed to investigate antibacterial-induced thrombocytopenia using the China Hospital Pharmacovigilance System (CHPS) in conjunction with Visual Basic for Applications (VBA).

METHODS:

Between September 2011 and December 2022, a 2-phase workflow was employed to identify antibacterial-induced thrombocytopenia, including preliminary screening in phase (I) conducted by CHPS algorithms and causality assessment by trained pharmacists in phase (II) using VBA. The incidence of thrombocytopenia in each antibacterial was calculated, and comparisons were performed between paediatric and adult patients.

RESULTS:

CHPS algorithms identified 4080 cases from 485 238 admissions (including 223 735 admissions receiving at least 1 antibacterial treatment). After ruling out cases with chemotherapy and abnormal platelet count at admission, 3832 cases were available. Using VBA, pharmacists identified 1039 cases (1246 antibacterial treatments, 28 agents) as potential thrombocytopenia instances (κ = 0.89), with an incidence of 0.46%. All antibacterial treatments correlated temporally with thrombocytopenia. Carbapenems (meropenem 1.77%), glycopeptides (vancomycin 1.55%) and lincosamides (clindamycin 0.44%) were prominent causal groups. The highest incidences of thrombocytopenia in the cephalosporins and penicillins groups were ceftazidime (2.04%) and piperacillin/tazobactam (1.24%), respectively. Among all antibacterial treatments, clindamycin showed the shortest time to onset (TTO), and erythromycin showed the longest TTO. Paediatric patients exhibited a longer TTO (61 vs. 29 h), extended time to nadir (83 vs. 37 h), lower platelet nadir count values (110 vs. 92 × 109/L), and a higher severe case proportion (12.37 vs. 3.86%) when compared with adults.

CONCLUSION:

Different antibacterial agents exhibit varying incidences of thrombocytopenia, with notable disparities between adults and children in the characteristics of thrombocytopenia.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Br J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Br J Clin Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: China